

OPIC  
OFFICE DE LA PROPRIÉTÉ  
INTELLECTUELLE DU CANADA



CIPO  
CANADIAN INTELLECTUAL  
PROPERTY OFFICE

Office Mail EIA 9C9

(21)	(A1)	2,106,987
(22)		1996/10/02
(43)		1998/04/02

(51) Int.Cl. <sup>6</sup> A61K 31/70; A01K 67/027

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) Inhibitors of Core 2 GlcNAc-T and Use of the Inhibitors  
to Prevent or Treat Cardiomyopathy Associated with  
Diabetes

(72) King, George L. - U.S.A. ;  
Dennis, James W. - Canada ;  
Warren, Charles E. - Canada ;

(71) Mount Sinai Hospital Corporation - Canada ;

(57) 3 Claims

Notice: This application is as filed and may therefore contain an  
incomplete specification.

 Industrie  
Canada Industry  
Canada

OPIC CIPO

Canada

BEST AVAILABLE COPY

2186987

B&P File No.3153-195 /LMK

**ABSTRACT OF THE DISCLOSURE**

5

The invention relates to methods for preventing or treating cardiomyopathy associated with diabetes mellitus and hyperglycemia by inhibiting core 2 GlcNAc-T; methods for screening for substances that affect cardiomyopathy associated with diabetes mellitus and hyperglycemia; and methods and pharmaceutical compositions containing the substances  
10 for preventing or treating cardiomyopathy associated with diabetes mellitus and hyperglycemia.

B&amp;P File No. 3153-195/LMK

**Title: Inhibitors of UDP-GlcNAc:Gal $\beta$ 1-3GalNAc $\alpha$ R  $\beta$ 1-6 N-acetylglucosaminyltransferase (core 2 GlcNAc-T) and Use of the Inhibitors to Prevent or Treat Cardiomyopathy Associated with Diabetes**

5

**FIELD OF THE INVENTION**

The invention relates to methods for preventing or treating cardiomyopathy associated with diabetes mellitus and hyperglycemia by inhibiting UDP-GlcNAc:Gal $\beta$ 1-3GalNAc $\alpha$ R  $\beta$ 1-6 N-acetylglucosaminyltransferase (core 2 GlcNAc-T); methods for  
10 screening for substances that affect cardiomyopathy associated with diabetes mellitus and hyperglycemia; and methods and pharmaceutical compositions containing the substances for preventing or treating cardiomyopathy associated with diabetes mellitus and hyperglycemia.

**BACKGROUND OF THE INVENTION**

15 Cardiovascular diseases are the major cause of morbidity and mortality in diabetic patients, involving cardiac tissues as well as large vessels in the brain, heart, and lower extremities (1). In the heart, the majority of the cardiac failure is probably due to atherosclerotic processes in the coronary vessels, but multiple studies have documented that a sizeable number of diabetic patients suffer from congestive heart failure without  
20 significant coronary disease (2, 3). In addition, type I diabetic patients with < 5 yr of disease have been reported to have abnormal cardiac function in the absence of significant coronary vessel disease (4). These clinical findings are supported further by animal studies documenting biochemical and functional changes in the cardiac tissue shortly after induction of diabetes (5-8). From these results, it has been postulated that diabetes mellitus and its  
25 metabolic sequelae can induce a specific form of cardiomyopathy (8, 9).

As with other chronic complications of diabetes, the cardio-vascular changes once established are difficult to reverse, both in clinical and experimental settings (10-12). Most cardiovascular abnormalities are metabolically induced with a great deal of interest directed towards identifying alterations in gene expression induced by diabetes or hyperglycemia in  
30 the vasculature. Since thickening of basement membrane is a classical finding in diabetes microvasculature (10), many of the studies concerning glucose-regulated genes have

primarily focused on changes in the basement matrix components using cultured vascular cells (13, 14).

### **SUMMARY OF THE INVENTION**

The present inventors have shown a direct association between UDP-GlcNAc GalB1-  
5 3GalNAc $\alpha$ R B1-6 N-acetylglucosaminyltransferase (core 2 GlcNAc-T) and diabetic cardiovascular disease. In particular, core 2 GlcNAc-T activity was increased by 82% in diabetic hearts versus controls, while the enzymes GlcNAc-T1 and GlcNAc-TV responsible for N-linked glycosylation were unchanged. The results indicate that core 2 GlcNAc-T is specifically induced in the heart by diabetes or hyperglycemia.

10 Significantly, increased core 2 GlcNAc-T activity caused pathology in the heart of diabetic experimental animal models which is similar to that observed in the heart of diabetic patients after years with the condition. In particular, a transgenic mouse was made with core 2 GlcNAc-T expression driven by a cardiac myosin promoter. At 4 months, a marked hypertrophy of the left ventricle and general hypertrophy of the heart was observed

15 The findings by the present inventors indicate that inhibiting core 2 GlcNAc-T can be useful in preventing or treating cardiomyopathy associated with diabetes and hyperglycemia. It also permits the identification of substances which affect core 2 GlcNAc-T and which may be used in the prevention and treatment of cardiomyopathy associated with diabetes and hyperglycemia.

20 Therefore, broadly stated the present invention relates to a method of preventing or treating cardiomyopathy associated with diabetes and hyperglycemia in a subject comprising reducing core 2 GlcNAc-T activity. Levels of core 2 GlcNAc-T activity may be reduced by administering a substance which inhibits core 2 GlcNAc-T activity. Substances which inhibit core 2 GlcNAc-T activity include known inhibitors of core 2 GlcNAc-T activity,  
25 inhibitors identified using the methods described herein, and antisense sequences of a nucleic acid sequence encoding core 2 GlcNAc-T activity.

The invention also relates to a method for screening for a substance that may be used to prevent or treat cardiomyopathy associated with diabetes and hyperglycemia. In an embodiment of the invention, a method of screening for a substance for use in preventing  
30 or treating cardiomyopathy associated with diabetes and hyperglycemia is provided comprising assaying for a substance that inhibits core 2 GlcNAc-T activity. A substance

that inhibits core 2 GlcNAc-T activity may be identified by reacting core 2 GlcNAc-T with an acceptor substrate and a sugar nucleotide donor in the presence of a substance suspected of inhibiting core 2 GlcNAc-T, under conditions whereby the core 2 GlcNAc-T produces a reaction product, determining the amount of reaction product, and comparing the amount of reaction product to an amount obtained for a control in the absence of the substance, wherein lower amounts of reaction product with the substance indicate that the substance inhibits core 2 GlcNAc-T.

Substances which inhibit core 2 GlcNAc-T may also be identified using the methods of the invention by comparing the pattern and level of expression of core 2 GlcNAc-T in tissues and cells in the presence, and in the absence of the substance.

Substances which inhibit core 2 GlcNAc-T may also be assayed by treating a cell which expresses core 2 GlcNAc-T with a substance which is suspected of inhibiting core 2 GlcNAc-T activity, and assaying for Gal $\beta$ 1-3[GlcNAc $\beta$ 1-6]GalNAc $\alpha$ - associated with the cell.

Substances which inhibit transcription or translation of the gene encoding core 2 GlcNAc-T may be identified by transfecting a cell with an expression vector comprising a recombinant molecule containing a nucleic acid sequence encoding core 2 GlcNAc-T, the necessary elements for the transcription and/or translation of the nucleic acid sequence and a reporter gene, in the presence of a substance suspected of inhibiting transcription or translation of the gene encoding core 2 GlcNAc-T activity, and comparing the level of expression of core 2 GlcNAc-T or the expression of the protein encoded by the reporter gene with a control cell transfected with the nucleic acid molecule in the absence of the substance. The method can be used to identify transcription and translation inhibitors of the gene encoding core 2 GlcNAc-T.

The substances identified using the method of the invention may be used to prevent or treat cardiomyopathy associated with diabetes and hyperglycemia. Accordingly, the substances may be formulated into pharmaceutical compositions for administration to individuals suffering from this condition.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications

within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

5        Figure 1 are blots of differential expressed cDNA fragments (A) and Northern blot analysis (B and C) showing differential expression in control (C) and diabetic heart (D) of the cDNA fragments identified in Panel A;

Figure 2 shows the quantitation of changes induced by diabetes in mRNA levels for DH1 and clone 13 in heart and aorta;

10        Figure 3 shows the nucleotide and deduced amino acid sequence of DH1 identifying the sequence as core 2 GlcNAc-T;

Figure 4 is a Northern blot analysis for DH1 expression performed using 25  $\mu$ g total cellular RNA isolated from age-matched non-obese diabetic (NOD) control mice (C) and diabetic NOD mice (D);

15        Figure 5 is a Northern blot analysis for DH1 expression using 25  $\mu$ g total cellular RNA isolated from heart of control rat (C) and 2 week diabetic rat without insulin treatment (D) or with insulin treatment for 1 week (D +I);

Figure 6 (A) is a Northern blot analysis using 20  $\mu$ g total RNA isolated from aorta, brain, heart, kidney, liver, solcus muscle, and lung of control (C) and 2 week diabetic (D) rats, and the same blot reprobed with 36B4 cDNA as a control; and Panel (B) is a bar graph showing the quantitative changes in DH1 levels induced by diabetes in aorta, brain, heart, kidney, liver, lung, and skeletal muscle;

Figure 7 (A) is a blot of total cellular RNA from cultured cardiomyocytes (lanes 1-3), fibroblasts (lane 4), and rat aortic smooth muscle cells (lane 5), probed with DH1; and  
25        Panel (B) is a graph showing the quantitation of changes induced by 22 mM glucose or 100 nM insulin for DH1 expression in cultured cardiomyocytes;

Figure 8 are graphs showing core GlcNAc-T, GlcNAc-T1, and GlcNAc-TV activities in the heart of control (closed column) and two week diabetic rats; and

Figure 9 shows the nucleotide and amino acid sequence of human core 2 GlcNAc-T.

### **30 DETAILED DESCRIPTION OF THE INVENTION**

As discussed above, the present invention relates to a method of preventing or treating cardiomyopathy associated with diabetes and hyperglycemia comprising reducing

core 2 GlcNAc-T activity. Levels of core 2 GlcNAc-T activity may be reduced by administering a substance which inhibits core 2 GlcNAc-T activity, or inhibits transcription or translation of the gene encoding core 2 GlcNAc-T.

Substances which inhibit core 2 GlcNAc-T activity include known inhibitors of core 2 GlcNAc-T. Examples of inhibitors of core 2 GlcNAc-T include an analog of the acceptor substrate for core 2 GlcNAc-T such as Gal $\beta$ 1-3GalNAc $\alpha$ . Inhibitors of enzymes earlier on in the Golgi oligosaccharide processing pathway may also be used to inhibit core 2 GlcNAc-T derived product, for example UDP-Gal:GalNAc $\alpha$ R $\beta$ 1-3 galactosyltransferase or UDP-GalNAc:Ser/thr  $\alpha$ N-acetylgalactosyltransferase.

Recombinant molecules containing the nucleic acid sequence of core 2 GlcNAc-T in antisense orientation may be used to inhibit core 2 GlcNAc-T activity. The nucleic acid sequence shown in Figure 9 (see also GenBank Accession Nos. L41415, U41320, and U19265 ), or parts thereof, may be inverted relative to their normal presentation for transcription to produce antisense nucleic acid molecules. The antisense nucleic acid molecules may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. The antisense nucleic acid molecules or a part thereof, may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules, or to increase the physical stability of the duplex formed with mRNA or the native gene e.g. phosphorothiate derivatives and acridine substituted nucleotides. The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.

The invention also provides methods for screening for a substance that may be used to prevent or treat cardiomyopathy associated with diabetes and hyperglycemia. In an embodiment of the invention, a method of screening for a substance for use in preventing or treating cardiomyopathy associated with diabetes and hyperglycemia is provided comprising assaying for a substance that inhibits core 2 GlcNAc-T activity. A substance that inhibits core 2 GlcNAc-T activity may be identified by reacting core 2 GlcNAc-T with an acceptor substrate and a sugar nucleotide donor in the presence of a substance suspected of inhibiting core 2 GlcNAc-T, under conditions whereby the core 2 GlcNAc-T transfers

the sugar nucleotide donor to the acceptor substrate to produce a reaction product, determining the amount of reaction product, and comparing the amount of reaction product to an amount obtained for a control in the absence of the substance, wherein lower amounts of reaction product with the substance indicate that the substance inhibits core 2 GlcNAc-T.

5       The acceptor substrate may be an oligosaccharide, a glycopeptide, or a glycoprotein having the following minimal structure for the oligosaccharide portion  $\text{Gal}\beta 1-3\text{GalNAc}\alpha\text{-R}$  where R is any convenient group  $\alpha$  linked covalently to the 1 position of the GalNAc residue of the acceptor, for example p-nitrophenol, or octyl. The sugar nucleotide donor is uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) which can be labelled in the  
10 GlcNAc portion with radioactive groups or other nonradioactive groups which can be used for product detection. The concentration of the acceptor substrate and of the labelled UDP-GlcNAc in the reaction may range from 0.01 mM to 10mM and the duration of the reaction from 5 minutes to 24 hours.

Conditions are selected so that the core 2 GlcNAc-T transfers the sugar nucleotide  
15 donor to the acceptor substrate to produce a reaction product. The substrate and sugar donor are effective to interact with the core 2 GlcNAc-T within wide pH and temperature ranges, for example from about 5 to 8 and from about 30 to 45°C, preferably from 37°C.

The core 2 GlcNAc-T may be obtained from commercial sources, or prepared by expression of the gene encoding core 2 GlcNAc-T in host cells (for example, transfected  
20 CHO cells). A substance that inhibits core 2 GlcNAc-T activity may also be identified by treating a cell which expresses core 2 GlcNAc-T with a substance which is suspected of affecting core 2 GlcNAc-T activity, and assaying for  $\text{Gal}\beta 1-3[\text{GalNAc}\beta 1-6]\text{GalNAc}\alpha$  associated with the cell.  $\text{Gal}\beta 1-3[\text{GalNAc}\beta 1-6]\text{GalNAc}\alpha$  can be measured using a substance that binds to the oligosaccharide product either alone or in association with an attached  
25 glycoprotein. For example, cells expressing core 2 GlcNAc-T may be treated with a substance suspected of inhibiting core 2 GlcNAc-T activity. An antibody specific for the oligosaccharide product can be added and the amount of antibody binding can be compared to control cells which have not been treated with the substance and/or which do not express core 2 GlcNAc-T. Antibodies specific for core 2 GlcNAc-T may be obtained from  
30 commercial sources, for example 1B11 rat anti-mouse CD43 activation-associated isoform monoclonal antibody supplied by Pharmingen Inc.



Substances which inhibit core 2 GlcNAc-T include substances which inhibit transcription or translation of the gene encoding core 2 GlcNAc-T. Transcription inhibitors may be identified by transfecting a host cell with a recombinant molecule comprising a nucleic acid sequence encoding core 2 GlcNAc-T, the necessary elements for the transcription of the nucleic acid sequence, and a reporter gene, in the presence of a substance suspected of inhibiting transcription of the gene encoding core 2 GlcNAc-T, and comparing the level of mRNA or expression of the protein encoded by the reporter gene with a control cell transfected with the nucleic acid molecule in the absence of the substance. Translation inhibitors may be identified by transfecting a host cell with a recombinant molecule comprising a nucleic acid sequence encoding core 2 GlcNAc-T, the necessary elements for the transcription and translation of the nucleic acid sequence, and a reporter gene, in the presence of a substance suspected of inhibiting translation of the gene encoding core 2 GlcNAc-T, and comparing the level of expression of core 2 GlcNAc-T with a control cell transfected with the nucleic acid molecule in the absence of the substance.

15 A recombinant molecule comprising a nucleic acid sequence encoding core 2 GlcNAc-T may be constructed having regard to the sequence of the core 2 GlcNAc-T gene (see Figure 9) using chemical synthesis and enzymatic ligation reactions following procedures known in the art.

Suitable transcription and translation elements may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, or insect genes. Selection of appropriate transcription and translation elements is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such elements include: a transcriptional promoter and enhancer, an RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other genetic elements, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary transcription and translation elements may be supplied by the native gene and/or its flanking sequences.

30 Examples of reporter genes are genes encoding a protein such as  $\beta$ -galactosidase (e.g. lac Z), chloramphenicol, acetyl-transferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG.

Transcription of the reporter gene is monitored by changes in the concentration of the reporter protein such as  $\beta$ -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. This makes it possible to visualize and assay for expression of recombinant molecules to determine the effect of a substance on expression of the core 2 GlcNAc-T  
5 gene.

Mammalian cells suitable for carrying out the present invention include, for example, COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), and 293 (ATCC No. 1573). Suitable expression vectors for directing expression in mammalian cells generally include  
10 a promoter. Common promoters include SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.

Protocols for the transfection of mammalian cells are well known in the art and include calcium phosphate mediated electroporation, retroviral, and protoplast fusion-  
15 mediated transfection (see Sambrook et al., Molecular Cloning A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989).

The reagents suitable for applying the methods of the invention to identify substances that may be used to prevent or treat cardiomyopathy associated with diabetes and hyperglycemia may be packaged into convenient kits providing the necessary materials  
20 packaged into suitable containers. The kits may also include suitable supports useful in performing the methods of the invention.

Substances which inhibit core 2 GlcNAc-T activity may be incorporated into pharmaceutical compositions. Therefore, the invention also relates to a pharmaceutical composition comprising an inhibitor of core 2 GlcNAc-T activity and in particular a  
25 substance identified using the methods described herein. The pharmaceutical compositions of the invention contain the substance, alone or together with other active substances.

The substances identified using the method of the invention may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for  
30 administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. Administration of a therapeutically

active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be  
5 adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal  
10 application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to  
15 subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more  
20 pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

Recombinant molecules comprising an antisense sequence may be directly introduced into cells or tissues *in vivo* using delivery vehicles such as retroviral vectors, adenoviral vectors and DNA virus vectors. They may also be introduced into cells *in vivo*  
25 using physical techniques such as microinjection and electroporation or chemical methods such as coprecipitation and incorporation of DNA into liposomes. Recombinant molecules may also be delivered in the form of an aerosol or by lavage. Recombinant molecules comprising an antisense sequence may also be applied extracellularly such as by direct injection into cells.

30 Inhibitors of core 2 GlcNAc-T and pharmaceutical compositions containing the inhibitors have pharmaceutical utility in the prevention and treatment of cardiomyopathy associated with diabetes mellitus and hyperglycemia. The utility of the inhibitors of core

2 GlcNAc-T and compositions of the invention may be confirmed in animal experimental model systems.

The present invention also contemplates a transgenic non-human animal all of whose germ cells and somatic cells contain a DNA construct introduced into the animal, or an  
5 ancestor of the animal at an embryonic stage, the DNA construct when incorporated into the germ line of the animal being adapted to develop cardiomyopathy similar to that associated with diabetes mellitus and hyperglycemia. The transgenic animal of the invention is therefore highly suited for investigating the molecular and cellular events involved in cardiomyopathy associated with diabetes mellitus and hyperglycemia, and for *in vivo*  
10 testing of the efficacy of drugs in the prevention or treatment of cardiomyopathy associated with diabetes mellitus and hyperglycemia.

In accordance with one embodiment of the invention, the transgenic non-human animal contains a DNA construct comprising a gene encoding core 2 GlcNAc-T. In accordance with a preferred embodiment of the invention, the transgenic non-human animal  
15 contains a DNA construct comprising a gene encoding core 2 GlcNAc-T and a promoter which stimulates expression of the gene in the cardiovascular system. Suitable promoters include the cardiac myosin promoter.

The animals of the invention may be used to test substances for their efficacy in preventing or treating cardiomyopathy associated with diabetes mellitus and  
20 hyperglycemia. When an animal is treated with the substance to be tested and a reduced incidence of cardiomyopathy compared to untreated animals is observed, it is an indication of the efficacy of the substance in the prevention or treatment of cardiomyopathy associated with diabetes mellitus and hyperglycemia.

The following non-limiting examples are illustrative of the present invention:

## 25 Examples

### Example 1

The following materials and methods were used in the Example:

**Animals.** Male Sprague-Dawley rats (Taconic Farms, Inc. German Town, NY) weighing 180-200 grams were injected by the intraperitoneal route with STZ (80 mg/kg of body  
30 weight). STZ was dissolved in 20mM citrate buffer (pH 4.5) immediately before use. Cardiac tissue from spontaneous autoimmune-caused diabetic nonobese diabetic (NOD) mice and their contral littermates were graciously provided by Dr. Masakazu Hattori of the

Joslin Diabetes Center (Boston, MA) (19). Onset of diabetes was determined by the detection of urinary glucose and confirmed by blood glucose levels. Insulin pellets (Linshin, Scarborough, Canada) were implanted subcutaneously 1 wk after STZ injection in four STZ-diabetic rats for another week to normalize blood glucose level. The mean plasma blood glucose level in insulin-treated STZ-diabetic rats was not significantly different from control animals ( $4.8 \pm 0.5$  vs  $5.6 \pm 0.7$  mM), while, the mean body weight in the insulin-treated STZ-diabetic rats remained significantly less than control ( $270 \pm 17$  vs  $326 \pm 17$  grams respectively,  $P < 0.01$ ) but significantly greater than diabetic rats without insulin treatment ( $210 \pm 33$  grams), ( $P < 0.01$ ).

10 *mRNA differential display.* Rats were killed 2 wk after onset of diabetes. Cardiac ventricles and thoracic aorta were dissected and washed with ice-cold PBS, immediately frozen in liquid  $N_2$  then crushed into frozen powder. Pieces of aorta from three rats were combined into one sample. Total RNA was extracted using Ultraspec RNA isolation system (Biotecx Laboratories, Houston, TX). mRNA differential display was performed as previously reported (17, 18). Briefly, DNA-free RNA was obtained by treatment with DNase I (GIBCO BRL, Grand Island, NY) in the presence of placental RNase inhibitor (GIBCO BRL) for 30 min at  $37^\circ\text{C}$ . After phenol/chloroform extraction and ethanol precipitation, two reverse transcriptions were performed for each RNA sample using  $0.2 \mu\text{g}$  DNA-free total RNA in 1X reverse transcription buffer (PCR buffer) containing 10 mM DTT,  $20 \mu\text{M}$  each of dGTP, dATP, dTTP, and dCTP, and  $1 \mu\text{M}$  of either  $T_{12}$  NG or  $T_{12}$  NC oligonucleotide (Midland Certified Reagent Co., Midland, TX) where N is threefold degenerate for G, A, and C. The solution was heated at  $65^\circ\text{C}$  for 5 min and cooled to  $37^\circ\text{C}$ , then superscript reverse transcriptase (20 U) (GIBCO BRL) was added for 1 h. PCR was performed in reaction mixtures containing 0.1 vol of reverse transcription reaction mixture, 1X PCR buffer,  $2 \mu\text{M}$  each of dGTP, dATP, dTTP, and dCTP,  $10 \mu\text{Ci}$  [ $\alpha$ - $^{32}\text{S}$ ]-dATP,  $1 \mu\text{M}$  of the respective  $T_{12}$  NX oligonucleotide,  $0.2 \mu\text{M}$  of 20 different specific arbitrary 10-mer oligonucleotides (OP-ERON Technologies Inc., Alameda, CA) and 10 U of AmpliTaq DNA polymerase (Perkin-Elmer Cetus Corp. Norwalk, CT). The PCR reactions were initiated at  $95^\circ\text{C}$  for 1 min, amplified 40 cycles at  $94^\circ\text{C}$  for 45 s,  $40^\circ\text{C}$  for 90 s,  $72^\circ\text{C}$  for 30 s, and finished at  $72^\circ\text{C}$  for 15 min. DNA sequencing stop buffer (U.S. Biochemical, Inc., Cleveland, OH) was added to samples which were heated at  $80^\circ\text{C}$  for 2 min before loading on a 6% polyacrylamide sequencing gel (National Diagnostics, Atlanta, GA). After

electrophoresis, the gels were exposed to XAR-5 film (Eastman Kodak Co., Rochester NY) for 48 h. Bands evident under one glycemic condition and absent in the other were identified and the PCR repeated to confirm the findings.

**Band recovery and Northern blot analysis** Bands reproducibly exhibiting significant differences in expression were cut out and DNA was eluted by boiling in 10 mM Tris HCl and 1 mM EDTA solution for 30 min. After ethanol precipitation, the DNA was reamplified by PCR using appropriate primers and conditions described above except for dNTP concentrations of 20  $\mu$ M and no radioisotope. Products were visualized on 2% agarose gels, eluted, and used as probes for Northern blot analysis or subcloned. Total RNA (20-25  $\mu$ g) was fractionated by denaturing 1% formaldehyde agarose gel electrophoresis and transferred to BioTrans nylon membrane (ICN, Irvine, CA).  $^{32}$ P-labeled probes prepared by random priming using a commercially available kit (Amersham Corp., Arlington Heights, IL) were hybridized to UV cross-linked blots in 0.1 M Pipes, 0.2 M NaPO<sub>4</sub>, 0.1 M NaCl, 1 mM EDTA, 5% SDS, and 60  $\mu$ g/ml salmon sperm DNA at 65°C and washed in 0.5 x SSC, 5% SDS at 65°C for over 1 h. mRNA expression was quantified using a phosphorImager and standardized volume integration with the accompanying ImageQuant Analyzing Software version 3.3 (Molecular Dynamics, Sunnyvale, CA) and loading differences were normalized using 36B4 as standard cDNA probe (17, 18).

**DNA sequencing** Samples showing significant changes by Northern blot analysis were subcloned using the TA Cloning Kit (Invitrogen Corp., San Diego, CA). After the subcloned inserts were checked by Northern blot analysis, DNA sequencing was performed using commercially available Sequenase version 2.0 kit (U.S. Biochemical, Inc.). Gene database searches were performed at the National Center for Biotechnology Information (NCBI) using the BLAST network service.

**Construction of the diabetic heart cDNA library** Poly(A)<sup>+</sup> RNA was isolated from the total cellular RNA extracted from heart of diabetic rats using an oligo-dT cellulose column (Pharmacia LKB Biotechnology Piscataway, NJ) as previously described (17). cDNA was prepared and ligated into the EcoRI sites of Lambda gt 10 (Stratagene, Inc., La Jolla, CA) by standard methods (20). After packaging the DNA, *Escherichia coli* (C600) was infected with the phage and plated on a P150 plate yielding about  $5 \times 10^4$  independent plaque-forming units. Plaques were lifted onto nitrocellulose (Schleicher & Schuell, Inc., Keene,

NH) and cross-linked to the membrane by ultraviolet light. 20 P150 plates were screened, which provided  $1 \times 10^6$  plaque-forming units for screening.

*Screening the cDNA library:* A 214-bp cDNA (DH1) probe obtained from differential display was hybridized to the cDNA library by standard methods at 44°C then washed at  
5 56°C (21). After screening  $1 \times 10^6$  plaque-forming units, a positive cDNA insert was isolated and subcloned into pBluescript (Stratagene, Inc.) For sequencing, the inserts were restricted using BamHI and EcoRI and subcloned into pBluescript.

*cDNA cloning of mouse UDP-GlcNAc 6Gal $\beta$ 1-3GalNAc-R  $\beta$ 1-6 N-acetylglucosaminyltransferase (core 2 GlcNAc-T).* Approximately  $2 \times 10^5$  colonies of a  
10 cDNA library prepared in pCDM8 (Invitrogen Corp.) using poly A<sup>+</sup> RNA from D33W25, a murine lymphoid tumor cell line (22), were screened by colony hybridization (23) to a 864-bp EcoRI-BamHI subcloned fragment of human core 2 GlcNAc-T isolated by PCR (gift of Dr. A. Datti, Perugia, Italy) corresponding to amino acids 85-372 of the human enzyme. Hybridization was performed overnight at 65°C in 500 mM sodium phosphate pH  
15 7.2, 7% SDS, 1% BSA, 1mM EDTA. After rinsing, filters were washed at 65°C in 100 mM sodium phosphate, 0.1% SDS. After three rounds of hybridization and purification, two clones, designated C2-251 and C2-352, were isolated and gave specific and strongly positive signals on Southern blots hybridized with the probe. The cDNA inserts were subcloned as XhoI fragments into SalI cut pGEM5zf(+) (Promega Corp., Madison, WI) and  
20 a series of exonuclease III-mung bean nuclease (GIBCO BRL) - nested deletions generated from each end. DNA sequencing was performed using the Autoread sequencing kit and the ALF DNA sequencer according to the manufacturer's instructions (Pharmacia LKB Biotechnology). Some sequences were also generated using internal primers. Data were analyzed and edited using the UWGCG suite.

25 *Transient expression of DH1 in Cos<sup>7</sup> cells* A cDNA insert containing the full open reading frame of DH1 was isolated with XhoI and EcoRV and subcloned into pcDNA1/amp (Invitrogen Corp.). The plasmid was purified by double CsCl ultracentrifugation followed by phenol/chloroform extraction (21), then DNA (0.5  $\mu$ g) was transfected into confluent Cos 7 cells cultured on P100 dishes using 20  $\mu$ g of Lipofectin for 16 h at 37°C (GIBCO  
30 BRL) (24). Cells were harvested 48 h later and used for measurement of core 2 GlcNAc transferase activity.

*Preparation of cardiomyocytes.* Cardiomyocytes were prepared by collagenase digestion as described before (25). Briefly, hearts were excised and perfused through the aorta with Krebs-Henseleit bicarbonate buffer containing 5.5 mM glucose and 2.5 mM calcium. The perfused medium was switched to the same buffer without calcium to stop contraction, followed by a final perfusion with Krebs-Henseleit buffer containing 50  $\mu$ M calcium, 0.1% BSA, 312 U/ml hyaluronidase (Worthington, Freehold, NJ) and 0.1% collagenase (Worthington). Ventricular tissue was dissociated by shaking in Krebs-Henseleit buffer containing 50  $\mu$ M calcium, 0.2% BSA, 312 U/ml hyaluronidase, and 0.1% collagenase. The cells were allowed to settle under gravity and were washed twice in the Krebs-Henseleit buffer containing 100  $\mu$ M calcium and 0.5% BSA before resuspension in minimal essential medium containing Earle's salts, 26 mM sodium bicarbonate, 5mM creatine, 20mM Hepes, 100 U/ml penicillin G, 100  $\mu$ g/ml streptomycin, and 1.8 mM calcium. The cells were seeded onto laminin-coated dishes and maintained in a 37°C humidified 0.5% air-5% CO<sub>2</sub> incubator. All cells were allowed to equilibrate for 2 h then washed and refed with the same media containing 0.24 gram % BSA and cultured for 3 d with the media changed daily. Some cells were cultured in the same media containing either 22mM glucose or 10<sup>-7</sup> M insulin for 3 d with daily changes of media.

*Measurement of core 2GlcNAc-T activity.* Transfected Cos-7 cells were washed in PBS, frozen, thawed, and lysed in 0.9% NaCl, 0.4% Triton X-100 at 0°C. PBS-rinsed, fresh frozen rat hearts were rinsed again in PBS and homogenized using a polytron in 0.9% NaCl, 0.4% Triton X-100, 0.1 mM PMSF, 0.1% Trasylol at 0°C. The core 2 GlcNAc transferase reactions contained 50mM 2-(N-morpholino) ethanesulfonic acid (MES) pH 7.0, 1 mM UDP-GlcNAc, 0.5  $\mu$ Ci UDP-6[<sup>3</sup>H]-N-acetylglucosamine (16,000 dpm/nmol, New England Nuclear, Boston, MA), 0.1 M GlcNAc, 1mM of Gal $\beta$ 1-3GalNAc $\alpha$ -pNp (Toronto Research Chemicals, Toronto, Canada) as substrate, and 16  $\mu$ l of cell lysate (8-12 mg/ml of protein) for a final volume of 32  $\mu$ l (26, 27). The GlcNAc-TV reactions were the same except that Triton X-100 was added to a final concentration of 1%, and 1 mM of GlcNAc $\beta$ 1-2Man $\alpha$ 1-OMan $\beta$ 1-O(CH<sub>2</sub>)<sub>6</sub>COOCH<sub>3</sub> (Dr. O. Hindsgaul, University of Alberta, Edmonton, Canada, was used as acceptor (28). The GlcNAcTI reactions were the same as GlcNAc-TV but with the addition of 10 mM MnCl<sub>2</sub>, and 1 mM Man $\alpha$ 1-3 (Man $\alpha$ 1-6) Man $\beta$ 1-O(CH<sub>2</sub>)<sub>6</sub>COOCH<sub>3</sub> was used as acceptor (29). Reactions were incubated for either 1 or 2 h at 37°C, then diluted to 5 ml in H<sub>2</sub>O and applied to a C<sub>18</sub> Sep-Pak (Millipore Corp.,



Bedford, NA) in H<sub>2</sub>O, washed with 20 ml H<sub>2</sub>O. The products were eluted with 5 ml of methanol and radioactivity was counted in a liquid scintillation  $\beta$ -counter. Endogenous enzymatic activity was measured in the absence of acceptor and subtracted from values determined in the presence of added acceptor.

- 5 *Statistical analysis.* Differences in signal intensity between controls and diabetic animals were expressed as percentage of controls. Because percentages tends to deviate from normal distribution, mean and standard error were calculated after transformation of data to logarithmic values and data were expressed as mean ( $\pm$ SE range). Statistical analysis (Student's *t* test) was performed using the logarithmic values.

## 10 RESULTS

*Differential display.* The expression of mRNA species derived from the cardia: ventricles of diabetic and control rats was compared using mRNA differential display. Approximately 2,000, presumably different, mRNA species were screened in this study using 40 combinations of primer sets. As exemplified by Figure 1 (A), eight candidates appeared  
15 Differentially expressed when ventricular tissue from control and diabetic rats was compared; five increased and three decreased their expression in the diabetic state. These changes were confirmed by repetition at least twice using different preparations of total RNA.

*Northern blot analysis.* Signals from all the candidates were detectable by Northern blot  
20 analysis using total RNA preparations. As shown in Figure 1 (B), two of the eight candidate species showed significant and reproducible changes in diabetic rats compared to controls. Figure 2 demonstrates that in rats diabetic for 2 wk, the level of DH1 (5.0 kb) increased to 680% (580-790%,  $n = 8$ ,  $P < 0.001$ ) of control in the heart but was not detectable in the aorta. Furthermore, in rats with diabetes for just 1 wk, the mRNA level of DH1 in the heart  
25 had already significantly increased to 410% of control levels. A significant increase of DH1 in the heart of diabetic rats was observed even after 4 wk of disease. The expression of clone 13 mRNA increased to 350% (260-470%,  $n = 3$ ,  $P < 0.05$ ) of control in the heart and decreased to 43% (38-49%,  $n=3$ ,  $P < 0.05$ ) of control in the aorta.

*Sequence analysis of DH1 and clone 13.* The nucleotide sequences of cDNA fragments of  
30 DH1 and clone 13 derived from differential display were determined. Both had flanking primer sequences identical to those used in the differential display. Searching the national gene databases (GenBank/EMBL) revealed that clone 13 had 99% identity to the Wistar rat

mitochondrial 16S ribosomal (30) while DH1, which was 214 bp in size, did not reveal any homology to previously reported sequences

*Cloning of full-length DH1 cDNA.* To facilitate identification, a cDNA library derived from diabetic rat heart mRNA was screened using the 214-bp-cloned DH1 PCR fragment as a probe. Five overlapping recombinants were identified and the composite of the full cDNA sequence was determined (Figure 3 (A)). It contained 5,010 bp inclusive of poly A tail and corresponded to the size detected by the original Northern blot analysis. Open reading frame analysis showed that the longest possible coding region which was from position 802 to 2085 and encoded 428 amino acids. The GXXATGC pattern was observed flanking the region of the presumptive start codon (31) and a polyadenylation signal, AATAAA, was found 15 bp upstream from the polyA tail. Searches for homologous sequences in Genbank/EMBL revealed that this cDNA shared 80% identity at the nucleotide level and 85% identity at the amino acid level with human core 2 (GlcNAc-T) (32). The mouse core 2 GlcNAc-T was also cloned and sequenced and it was found that DH1 shared 92% identity with the amino acid sequence of mouse core 2 GlcNAc-T (Figure 3 (B)). These findings strongly suggested that DH1 was rat core 2 GlcNAc-T.

*Characterization of DH1 expression in the NOD mouse.* To check that increased expression of DH1 was diabetes specific and not due to other effects of streptozotocin, DH1 expression in the hearts of spontaneous autoimmune-caused diabetic NOD mice was measured. As shown in Figure 4, DH1 hybridizing signals were detected by Northern blot analysis at 6.0, 4.6, and 1.9 kb from animals which had experienced 2-3 wk of hyperglycemia and diabetes. The 4.6 and 6.0 kb bands in hearts from diabetic NOD mice increased to 560% of control animals.

*Effects of insulin on DH1 expression in diabetic rats.* After 1 wk of diabetes, four rats were treated with insulin for an additional week. Blood glucose level was normalized from 24.7 to 4.8 mM ( $P < 0.01$ ). The Northern blot analysis shown in Figure 5, demonstrated that cardiac expression of DH1 in rats diabetic for 2 wk increased to 680% of control levels, consistent with earlier data, whereas insulin treatment normalized the expression of the DH1 to 169% (134-214%  $P < 0.001$  vs 2-wk diabetic rats) of control levels.

*Tissue distribution of DH1.* Figure 6 (A) shows a representative Northern blot analysis of DH1 expression using total cellular RNA isolated from tissues of control and diabetic rats. Relative signal intensity was calculated using the 36B4 signal for normalization and is

shown in Figure 6 (B). In normal rats, DH1 transcripts were relatively high in the brain, kidney and liver and low in the heart, aorta, lungs, and skeletal (soleus) muscle. A significant and cardiac specific increase (6.8-fold) in the expression of DH1 mRNA was observed in diabetic animals.

- 5 *The expression of DH1 in cultured cells.* Cultured cardiomyocytes were measured to determine whether they could be the source of the increased expression of DH1. As shown in Figure 7 (A,) DH1 hybridizing signals were detected by Northern blot analysis of cultured cardiomyocytes at the same mobility as the mRNA from heart tissue (5.0 kb). However, DH1 expression was not detectable in fibroblasts cultured from rat heart or rat aortic smooth  
10 muscle cells even when using 25  $\mu$ g of total cellular RNA. Furthermore, in cardiomyocytes, cultures elevating media glucose concentration from 5.5 to 22 mM increased the expression of the DH1 by 78% (54-106%,  $P<0.05$ ) while insulin ( $10^{-7}$ M) decreased the expression by 53% (40-62%,  $P<0.05$ ) of control levels as shown in Figure 7 (B).

- Core 2 GlcNAc-T activity in cells transiently transfected with DH1.* Although Cos 7 cells  
15 lipofected with pcDNA1/amp showed significant endogenous core 2 GlcNAc-T activity of  $1.71 \pm 0.27$  nmol/mg per h ( $n=3$ ), cells transfected with the expression vector containing a full-length cDNA for DH1 in correct orientation had  $3.85 \pm 1.6$  nmol/mg per h ( $P<0.05$ ,  $n=3$ ). The assay is specific for core 2 GlcNAc-T, as confirmed by analysis of the reaction product Gal $\beta$ 1-3[GlcNAc $\beta$ 1-6]-GalNAc-pNp by  $^1$ H-NMR (Nuclear Magnetic Resonance)  
20 and HPLC which had been reported in previous studies (28). Therefore, DH-1 encodes an enzymatically active core-2 GlcNAc-T.

- GlcNAc-T activity in heart.* With the identification of DH1 being an enzyme involved in mediating the biosynthesis of O-linked sugar chains, the specificity of the diabetes effect was tested by measuring the activities of core 2 GlcNAc-T (which branches maturing O-  
25 linked sugar chains) and two other GlcNAc transferases (which are specific for branching N-linked sugar chains) in the hearts of control and diabetic rats (Figure. 8). Core 2 GlcNAc-T activity increased significantly and specifically in diabetic hearts by 82% of control ( $0.39 \pm 0.03$  vs  $0.71 \pm 0.10$  nmol/h per mg protein  $n=3$ ,  $P<0.05$ ). In contrast, GlcNAc-TI and GlcNAc-TV activities were not significantly different between control and diabetes  
30 (GlcNAc-TI:  $1.05 \pm 0.11$  vs  $0.79 \pm 0.09$  nmol/h per mg protein, GlcNAc-TV:  $0.078 \pm 0.024$  vs  $0.077 \pm 0.023$  nmol/h per mg protein). The changes thus seem restricted to O-glycosylation.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the  
5 appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

## FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

1. Keasler, I. I. 1971. Mortality experience of diabetic patients. *Am. J. Med.* 51:715-724.
2. Rubler, S., J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Girschman. 1972. New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am. J. Cardiol.* 30:595-602.
3. Kannel, W. B., M. Hjortland, and W. P. Castelli. 1974. Role of diabetes in congestive heart failure: the Framingham study. *Am. J. Cardiol.* 34:29-34.
4. Lababidi, Z. A., and D. E. Goldstein. 1983. High prevalence of echocardiographic abnormalities in diabetic youths. *Diabetes Care.* 6:18-22.
5. Reagan, T. J., P. O. Ettinger, M. I. Khan, M. U. Jesrani, M. M. Lyons, H. A. Oldewurtel, and M. Weber. 1974. Altered myocardial function and metabolism in chronic diabetes mellitus without ischemia in dogs. *Circ. Res.* 35:222-237.
6. Fein, P. S., J. E. Strobeck, A. Malhotra, J. Scheuer, and E. H. Sonnenblick. 1981. Reversibility of diabetic cardiomyopathy with insulin in rats. *Circ. Res.* 49:1251-1261.
7. Nishio, Y., A. Kashiwagi, Y. Kida, M. Kodama, N. Abe, Y. Saeki, and Y. Shigeta. 1988. Deficiency of cardiac B-adrenergic receptor in streptozocin-induced diabetic rats. *Diabetes.* 37:1181-1187.
8. Reagan, T. J., M. M. Lyons, S. S. Ahmed, G. E. Levinson, H. A. Oldewurtel, M. R. Ahmad, and B. Haider. 1977. Evidence for cardiomyopathy in familial diabetes mellitus. *J. Clin. Invest.* 60:885-899.
9. Factor, S. M., T. Minase, and E. H. Sonnenblick. 1980. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. *Am. Heart J.* 99:446-458.
10. Engerman, R. J., and T. S. Kern. 1987. Progression of incipient diabetic retinopathy during good glycemic control. *Diabetes.* 36:808-812.
11. Inoguchi, T., R. Battan, E. Handler, J. R. Sportsman, W. Heath, and G. L. King. 1992. Preferential elevation of protein kinase C isoform BII and diacylglycerol level in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. *Proc. Natl. Acad. Sci. USA.* 89:11059-11063.
12. Nishio, Y., A. Kashiwagi, T. Ogawa, T. Asahina, M. Ikebuchi, M. Kodama, and Y. Shigeta. 1990. Increase in [<sup>3</sup>H] PN200-110 binding to cardiac muscle membrane in streptozocin-induced diabetic rats. *Diabetes.* 39:1064-1069.
13. Cagliero, E., M. Maiello, D. Boz, S. Roy, and M. Lorenzi. 1988. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. *J. Clin. Invest.* 82:735-738.
14. Ayo, S. H., R. A. Radink, W. F. Glass II, J. A. Garoni, E. R. Rumpf, D. R. Appling, and J. L. Kreisberg. 1990. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. *Am. J. Pathol.* 136:1339-1348.
15. Liang, P., and A. B. Pardee. 1992. Differential display of eukaryotic messenger RNA by means of polymerase chain reaction. *Science (Wash. DC)* 257:967-971.
16. Liang, P., L. Averboukh, K. Keyomarsi, R. Sager, and A. B. Pardee. 1992. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. *Cancer Res.* 52:6966-6968.
17. Nishio, Y., L. P. Aiello, and G. L. King. 1994. Glucose induced genes in bovine aortic smooth muscle cells identified by mRNA differential display. *FASEB (Fet. Am. Soc. Exp. Biol.) J.* 8:103-106.
18. Aiello, L. P., O. S. Robinson, Y. W. Lin, Y. Nishio, and G. L. King. 1994. Identification of multiple glucose-regulated genes in bovine retinal pericytes by mRNA differential display. *Proc. Natl. Acad. Sci. USA.* 91:6231-6235.
19. Ikegami, H., O. S. Eisenbarth, and M. Hattori. 1991. Major histocompatibility complex-linked diabetogenic gene of the nonobese diabetic mouse. Analysis of genomic DNA amplified by the polymerase chain reaction. *J. Clin. Invest.* 85:18-24.

20. Klickstein, L. B., and L. R. Nerve. 1991. Construction of recombinant DNA libraries. In *Current Protocols in Molecular Biology*. F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, editors. John Wiley & Sons, New York. 5.0.1-5.6.10.
21. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular Cloning*. Cold Spring Harbor Laboratory, Cold Spring, NY.
22. Dennis, J. W. 1985. Different metastatic phenotypes and two genetic classes of wheat germ agglutinin-resistant tumor cell mutants. *Cancer Res.* 46:4594-4600.
23. Weis, J. H. 1991. Plating and transferring cosmid and plasmid library. In *Current Protocols in Molecular Biology*. F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, editors. John Wiley & Sons, New York. 6.2.1-6.2.3.
24. Felgner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. Northrup, G. M. Ringold, and M. Danielsen. 1987. Lipofection: a highly efficient, lipid-mediated DNA transfection procedure. *Proc. Natl. Acad. Sci. USA.* 84:7413-7417.
25. Buczek-Thomas, J. A., S. R. Jaspers, and T. B. Miller, Jr. 1992. Adrenergic activation of glycogen phosphorylase in primary culture diabetic cardiomyocytes. *Am. J. Physiol.* 262:H649-H653.
26. Williams, D., and H. Schachter. 1980. Mucin synthesis. I. Detection in canine submaxillary glands of an N-acetylglucosaminyltransferase which acts on mucin substrates. *J. Biol. Chem.* 255:11247-11252.
27. Datti, A., and J. W. Dennis. 1993. Regulation of UDP-GlcNAc:GalB1-3GalNAc-R B1-6-N-acetylglucosaminyltransferase (GlcNAc to GalNAc) in Chinese hamster ovary cells. *J. Biol. Chem.* 268:5409-5416.
28. Yousefi, S., E. Higgins, Z. Doaling, O. Hindsgaul, A. Pollex-Kruger, and J. W. Dennis. 1991. Increased UDP-GlcNAc:Gal B1-3GalNAc-R (GlcNAc to GalNAc) B1-6 N-acetylglucosaminyltransferase activity in transformed and metastatic murine tumor cell lines: control of polylactosamine synthesis. *J. Biol. Chem.* 266:1772-1783.
29. Moller, G., F. Reck, H. Paulsen, K. J. Kaur, M. Sarkar, H. Schachter, and I. Brockhausen. 1992. Control of glycoprotein synthesis: substrate specificity for rat liver UDP-GlcNAc:Man $\alpha$ 3R B2-N-acetylglucosaminyl-transferase I using synthetic substrate analogues. *Glycoconj. J.* 9:180-190.
30. Kobayashi, M., T. Seki, K. Yaginuma, and K. Koike. 1981. Nucleotide sequences of small ribosomal RNA and adjacent transfer RNA genes in rat mitochondrial DNA. *Gene.* 16:297-307.
31. Carverer, D. R., and S. C. Ray. 1991. Eukaryotic start and stop translation sites. *Nucleic Acids Res.* 19:3185-3192.
32. Bierhuizen, M. F., and M. Fukuda. 1992. Expression cloning of a cDNA encoding UDP-GlcNAc:GalB1-3GalNAc-R(GlcNAc to GalNAc) B1-GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. *Proc. Natl. Acad. Sci. USA.* 89:9326-9330.
33. Ledet, T. 1961. Histological and histochemical changes in the coronary arteries of old diabetic patients. *Diabetologia.* 4:268-272.
34. Camps, M., A. Castello, P. Munoz, M. Monfar, X. Testar, M. Palacin, and A. Zorzano. 1992. Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter expression in insulin-sensitive tissue. Heterogeneous response in heart, red and white muscle. *Biochem. J.* 282:765-772.
35. Zarain, H. A., K. Yano, V. Elimban, and N. S. Dhalla. 1994. Cardiac sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase expression in streptozotocin-induced diabetic rat heart. *Biochem. Biophys. Res. Commun.* 203:113-120.
36. Hsiao, Y. C., K. Suzuki, H. Abe, and T. Toyota. 1987. Ultrastructural alterations in cardiac muscle of diabetic BB Wistar rats. *Virchows. Arch. A. Pathol. Anat. Histopathol.* 411:45-52.


37. Reinila, A., and H. K. Akerblom. 1984. Ultrastructure of heart muscle in short-term diabetic rats: influence of insulin treatment. *Diabetologia*. 27:397-402.
38. Jackson, C. V., G. M. McGrath, A. G. Tahilliani, R. V. Vadlamudi, and J. H. McNeill. 1985. A functional and ultrastructural analysis of experimental diabetic rat myocardium. Manifestation of a cardiomyopathy. *Diabetes*. 34:876-883.
39. Kuo, T. H., K. H. Moore, F. Giacomelli, and J. Wiener. 1983. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. *Diabetes*. 32:781-787.
40. Clayton, D. A. 1984. Transcription of the mammalian mitochondrial genome. *Annu. Rev. Biochem.* 53:573-594.
41. Lee, Y.-C., N. Kojima, E. Wada, N. Kurosawa, T. Nakaoka, T. Imanamoto, and S. Tsuji. 1994. Cloning and expression of cDNA for a new type of Gal $\beta$ 1,3-GalNAc  $\alpha$ 2,3-Sialyltransferase. *J. Biol. Chem.* 269:10028-10033.
42. Sachs, A. B. 1993. Messenger RNA degradation in eukaryotes. *Cell*. 74:413-421.
43. Brockhausen, I., W. Kuhns, H. Schachter, K. L. Matta, D. R. Sutherland, and M. A. Baker. 1991. Biosynthesis of O-glycans in leukocytes from normal donors and from patients with leukemia: Increase in O-glycan core 2 UDP-GlcNAc:GalB3GalNAc-R (GlcNAc to GalNAc) B(1-6)-N-acetylglucosaminyl-transferase in leukemic cells. *Cancer Res.* 51:1257-1263.
44. Saitoh, F., F. Piller, R. I. Fox, and M. Fukuda. 1991. T-lymphocytic leukemia expresses complex branched O-linked oligosaccharides on a major sialoglycoprotein, Leukosialin. *Blood*. 77:1491-1499.
45. Piller, F., F. L. Deist, K. I. Weinberg, R. Parkman, and M. Fukuda. 1991. Altered O-glycan synthesis in lymphocytes from patients with Wiskott-Aldrich Syndrome. *J. Exp. Med.* 173:1501-1510.
46. Roy, S., M. Maiello, and M. Lorenzi. 1994. Increased expression of basement membrane collagen in human diabetic retinopathy. *J. Clin. Invest.* 93:438-442.
47. Fukui, M., T. Nakamura, I. Ebihara, I. Shirato, Y. Tomino, and H. Koide. 1992. ECM gene expression and its modulation by insulin in diabetic rats. *Diabetes*. 41:1520-1527.
48. Shanker, R., W. E. Neeley, and W. H. Dillmann. 1986. Rapid effects of insulin on in vitro translational activity of specific mRNA in diabetic rat heart. *Am. J. Physiol.* 250:E558-E563.
49. Page, M. M., R. B. Smith, and D. P. Watkins. 1976. Cardiovascular effects of insulin. *Br. Med. J.* 1:430-432.
50. O'Brien, M. R., and D. K. Granner. 1990. PEPCK gene as model of inhibitory effects of insulin on gene transcription. *Diabetes Care*. 13:327-339.
51. Bornfeldt, K. E., A. Skottener, and H. J. Arnqvist. 1992. In vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle. *J. Endocrin.* 135:203-211.
52. Dillmann, W. H. 1989. Diabetes and thyroid-hormone-induced changes in cardiac function and their molecular basis. *Annu. Rev. Med.* 40:373-394.

**We Claim:**

1. A method of preventing or treating cardiomyopathy associated with diabetes and hyperglycemia in a subject comprising reducing core 2 GlcNAc-T activity. Levels of core 2 GlcNAc-T activity may be reduced by administering a substance which  
5 inhibits core 2 GlcNAc-T activity. Substances which inhibit core 2 GlcNAc-T activity include known inhibitors of core 2 GlcNAc-T activity, inhibitors identified using the methods described herein, and antisense sequences of the nucleic acid sequence encoding core 2 GlcNAc-T activity.
- 10 2. A method for screening for a substance that may be used to prevent or treat cardiomyopathy associated with diabetes and hyperglycemia comprising reacting core 2 GlcNAc-T with an acceptor substrate and a sugar nucleotide donor in the presence of a substance suspected of inhibiting core 2 GlcNAc-T, under conditions whereby the core 2  
15 GlcNAc-T produces a reaction product, determining the amount of reaction product, and comparing the amount of reaction product to an amount obtained for a control in the absence of the substance, wherein lower amounts of reaction product with the substance indicate that the substance inhibits core 2 GlcNAc-T.
3. A transgenic non-human animal all of whose germ cells and somatic  
20 cells contain a DNA construct introduced into the animal, or an ancestor of the animal at an embryonic stage, the DNA construct when incorporated into the germ line of the animal being adapted to develop cardiomyopathy similar to that associated with diabetes mellitus and hyperglycemia.



## FIGURE 1



Samples represent 25  $\mu$ g per lane of total cellular RNA isolated from heart ventricles and aorta of either control (C) or diabetic (D) rats.

*Figure 1. Differential mRNA display (A) and Northern blot analysis (B and C) of the differentially expressed cDNA fragments. Candidate cDNA signals which demonstrate altered expression by differential mRNA are marked by arrowheads in (A). (B) Northern blot analysis using [ $^{32}$ P]dATP labeled cDNA probes derived from reamplification of molecules marked by arrowheads in (A).*

FIGURE 2




Figure 2. Quantitation of changes induced by diabetes in mRNA level for DH1 and clone 13 in heart and aorta is shown. Data are expressed as percentage of control. Closed circle represents the 2-wk diabetes and open circle represents 1-wk diabetes. Each point represents the change in Northern blot analysis using 20–25  $\mu$ g total cellular RNA obtained from different animals. \*  $P < 0.001$ , \*  $P < 0.05$  compared with control.

# FIGURE 3A


2186987

A

A - 601  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871  
 872  
 873  
 874  
 875  
 876  
 877  
 878  
 879  
 880  
 881  
 882  
 883  
 884  
 885  
 886  
 887  
 888  
 889  
 890  
 891  
 892  
 893  
 894  
 895  
 896  
 897  
 898  
 899  
 900  
 901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948  
 949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979  
 980  
 981  
 982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998  
 999  
 1000  
 1001  
 1002  
 1003  
 1004  
 1005  
 1006  
 1007  
 1008  
 1009  
 1010  
 1011  
 1012  
 1013  
 1014  
 1015  
 1016  
 1017  
 1018  
 1019  
 1020  
 1021  
 1022  
 1023  
 1024  
 1025  
 1026  
 1027  
 1028  
 1029  
 1030  
 1031  
 1032  
 1033  
 1034  
 1035  
 1036  
 1037  
 1038  
 1039  
 1040  
 1041  
 1042  
 1043  
 1044  
 1045  
 1046  
 1047  
 1048  
 1049  
 1050  
 1051  
 1052  
 1053  
 1054  
 1055  
 1056  
 1057  
 1058  
 1059  
 1060  
 1061  
 1062  
 1063  
 1064  
 1065  
 1066  
 1067  
 1068  
 1069  
 1070  
 1071  
 1072  
 1073  
 1074  
 1075  
 1076  
 1077  
 1078  
 1079  
 1080  
 1081  
 1082  
 1083  
 1084  
 1085  
 1086  
 1087  
 1088  
 1089  
 1090  
 1091  
 1092  
 1093  
 1094  
 1095  
 1096  
 1097  
 1098  
 1099  
 1100  
 1101  
 1102  
 1103  
 1104  
 1105  
 1106  
 1107  
 1108  
 1109  
 1110  
 1111  
 1112  
 1113  
 1114  
 1115  
 1116  
 1117  
 1118  
 1119  
 1120  
 1121  
 1122  
 1123  
 1124  
 1125  
 1126  
 1127  
 1128  
 1129  
 1130  
 1131  
 1132  
 1133  
 1134  
 1135  
 1136  
 1137  
 1138  
 1139  
 1140  
 1141  
 1142  
 1143  
 1144  
 1145  
 1146  
 1147  
 1148  
 1149  
 1150  
 1151  
 1152  
 1153  
 1154  
 1155  
 1156  
 1157  
 1158  
 1159  
 1160  
 1161  
 1162  
 1163  
 1164  
 1165  
 1166  
 1167  
 1168  
 1169  
 1170  
 1171  
 1172  
 1173  
 1174  
 1175  
 1176  
 1177  
 1178  
 1179  
 1180  
 1181  
 1182  
 1183  
 1184  
 1185  
 1186  
 1187  
 1188  
 1189  
 1190  
 1191  
 1192  
 1193  
 1194  
 1195  
 1196  
 1197  
 1198  
 1199  
 1200  
 1201  
 1202  
 1203  
 1204  
 1205  
 1206  
 1207  
 1208  
 1209  
 1210  
 1211  
 1212  
 1213  
 1214  
 1215  
 1216  
 1217  
 1218  
 1219  
 1220  
 1221  
 1222  
 1223  
 1224  
 1225  
 1226  
 1227  
 1228  
 1229  
 1230  
 1231  
 1232  
 1233  
 1234  
 1235  
 1236  
 1237  
 1238  
 1239  
 1240  
 1241  
 1242  
 1243  
 1244  
 1245  
 1246  
 1247  
 1248  
 1249  
 1250  
 1251  
 1252  
 1253  
 1254  
 1255  
 1256  
 1257  
 1258  
 1259  
 1260  
 1261  
 1262  
 1263  
 1264  
 1265  
 1266  
 1267  
 1268  
 1269  
 1270  
 1271  
 1272  
 1273  
 1274  
 1275  
 1276  
 1277  
 1278  
 1279  
 1280  
 1281  
 1282  
 1283  
 1284  
 1285  
 1286  
 1287  
 1288  
 1289  
 1290  
 1291  
 1292  
 1293  
 1294  
 1295  
 1296  
 1297  
 1298  
 1299  
 1300  
 1301  
 1302  
 1303  
 1304  
 1305  
 1306  
 1307  
 1308  
 1309  
 1310  
 1311  
 1312  
 1313  
 1314  
 1315  
 1316  
 1317  
 1318  
 1319  
 1320  
 1321  
 1322  
 1323  
 1324  
 1325  
 1326  
 1327  
 1328  
 1329  
 1330  
 1331  
 1332  
 1333  
 1334  
 1335  
 1336  
 1337  
 1338  
 1339  
 1340  
 1341  
 1342  
 1343  
 1344  
 1345  
 1346  
 1347  
 1348  
 1349  
 1350  
 1351  
 1352  
 1353  
 1354  
 1355  
 1356  
 1357  
 1358  
 1359  
 1360  
 1361  
 1362  
 1363  
 1364  
 1365  
 1366  
 1367  
 1368  
 1369  
 1370  
 1371  
 1372  
 1373  
 1374  
 1375  
 1376  
 1377  
 1378  
 1379  
 1380  
 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398  
 1399  
 1400  
 1401  
 1402  
 1403  
 1404  
 1405  
 1406  
 1407  
 1408  
 1409  
 1410  
 1411  
 1412  
 1413  
 1414  
 1415  
 1416  
 1417  
 1418  
 1419  
 1420  
 1421  
 1422  
 1423  
 1424  
 1425  
 1426  
 1427  
 1428  
 1429  
 1430  
 1431  
 1432  
 1433  
 1434  
 1435  
 1436  
 1437  
 1438  
 1439  
 1440  
 1441  
 1442  
 1443  
 1444  
 1445  
 1446  
 1447  
 1448  
 1449  
 1450  
 1451  
 1452  
 1453  
 1454  
 1455  
 1456  
 1457  
 1458  
 1459  
 1460  
 1461  
 1462  
 1463  
 1464  
 1465  
 1466  
 1467  
 1468  
 1469  
 1470  
 1471  
 1472  
 1473  
 1474  
 1475  
 1476  
 1477  
 1478  
 1479  
 1480  
 1481  
 1482  
 1483  
 1484  
 1485  
 1486  
 1487  
 1488  
 1489  
 1490  
 1491  
 1492  
 1493  
 1494  
 1495  
 1496  
 1497  
 1498  
 1499  
 1500  
 1501  
 1502  
 1503  
 1504  
 1505  
 1506  
 1507  
 1508  
 1509  
 1510  
 1511  
 1512  
 1513  
 1514  
 1515  
 1516  
 1517  
 1518  
 1519  
 1520  
 1521  
 1522  
 1523  
 1524  
 1525  
 1526  
 1527  
 1528  
 1529  
 1530  
 1531  
 1532  
 1533  
 1534  
 1535  
 1536  
 1537  
 1538  
 1539  
 1540  
 1541  
 1542  
 1543  
 1544  
 1545  
 1546  
 1547  
 1548  
 1549  
 1550  
 1551  
 1552  
 1553  
 1554  
 1555  
 1556  
 1557  
 1558



FIGURE 4



*Figure 4. Northern blot analysis of DH1 was performed using 25  $\mu$ g total cellular RNA isolated from age-matched NOD control mice (C) and diabetic NOD mice (D). The same blot was re-probed with 36B4 cDNA as a loading control.*

FIGURE 5




Figure 5. Effect of insulin treatment on DH1 expression in rat hearts is shown. The arrow indicates the DH1 signal in Northern blot analysis using 25  $\mu$ g total cellular RNA isolated from heart of control rat (C) and 2-wk diabetic rat without insulin treatment (D) or with insulin treatment for 1-wk (D + I). The same blot was reprobbed with 36B4 cDNA as a loading control.

FIGURE 6





Figure 6. Tissue distribution of gene expression of DH1 is shown. (A), Northern blot analysis was performed using 20  $\mu$ g total cellular RNA isolated from aorta, brain, heart, kidney, liver, spleen, and lung of control (C) and 2-wk diabetic (D) rats. DH1 signals are indicated by an arrow. The same blot was reprobed with 3000 cDNA as a loading control. (B) Quantitation of changes induced by diabetes mRNA level for DH1 in aorta, brain, heart, kidney, liver, lung, and spleen muscle. Data are expressed relative to the average level of control rat heart. Closed bars represent control (C) and hatched bars represent 2-wk diabetic (DM). Results are shown as mean  $\pm$  SE of three experiments using different animals. \*  $P < 0.05$  as compared with control.

## FIGURE 7



**Figure 7** Northern blot analysis of DH1 mRNA. (A) Total cellular RNA from cultured cardiomyocytes (10  $\mu$ g) for lanes 1–3, fibroblasts (25  $\mu$ g) for lane 4, and rat aortic smooth muscle cells (25  $\mu$ g) for lane 5 were used. Cardiomyocytes were cultured as described in Methods with 5.5 mM glucose without insulin (C), 22 mM glucose without insulin (HG), or 5.5 mM glucose with 100 nM insulin (I) for 3 d. DH1 signals are indicated by an arrow. The same blot was reprobed with 36B4 cDNA as a loading control. (B) Quantitation of changes induced by 22 mM glucose or 100 nM insulin for DH1 expression in cultured cardiomyocytes. Data are expressed as percentage of control. Closed bar represents the results of cells cultured with 22 mM glucose and hatched bar represents the result of cells cultured with 100 nM insulin. Results are shown as mean  $\pm$  SE of four independent experiments. \*  $P < 0.05$  as compared with control.



FIGURE 8




Figure 8. GlcNAc-T activities in the heart of control (closed column) and 2-wk diabetic (hatched column) rats. Core 2 GlcNAc-T, GlcNAc-TI, and -TV activities were measured as described in Methods. Results are presented as mean  $\pm$  SE of three measurements using different animals. \*  $P < 0.05$  as compared with control.

2186987

## FIGURE 9

LOCUS HUMC2CNT 2204 bp DNA PRI 10-APR-1996  
 DEFINITION Homo sapiens core 2 beta-1,6-N-acetylglucosaminyltransferase (core 2 Gnt) gene, complete cds.  
 ACCESSION L41415  
 NID g886272  
 KEYWORDS beta-1,6-N-acetylglucosaminyltransferase.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 2204)  
 AUTHORS Bierhuizen, M.P., Maemura, K., Kudo, S. and Fukuda, M.  
 TITLE Genomic organization of core 2 and I branching beta-1,6-N-acetylglucosaminyltransferases. Implication for evolution of the beta-1,6-N-acetylglucosaminyltransferase gene family  
 JOURNAL Glycobiology 5 (4), 417-425 (1995)  
 MEDLINE 96078409  
 FEATURES  
 source 1..2204  
 /organism="Homo sapiens"  
 /note="(vector lambda EMBL3)"  
 /map="chromosome 9"  
 /tissue\_type="placenta"  
 intron <1..100  
 /number=1  
 exon 101..2204  
 /number=2  
 /codon\_start=1  
 CDS 244..1530  
 /gene="core 2 Gnt"  
 /EC\_number="2.4.1.102"  
 /note="core 2"  
 /codon\_start=1  
 /product="beta-1,6-N-acetylglucosaminyltransferase"  
 /db\_xref="PID:g886273"  
 /translation="MLRTLRLRRRLFSYPTKYFPMVLVLSLITFSVLRIHQKPEFVSVR  
 HLELAGENPSSDINCKVLQGDVNEIQVKLEILTVKPKRPRWTPDDYINMTSDCSS  
 FIKRRKYIVEPLSKEEAEPPIAYSIVVHHKIEMLDRLLRATYMPQNFYCVHVDY JED  
 SYLAAMVHGIA SCFSNVFVARSRLSVVYASWSRVQADLNCHMDLYAMSAWKYLINLCG  
 MDFFPIKTNLEIVRKLLMGNNLETERMP SHKEERWKORYEVVNGKLTNTGTVMQLP  
 PLETPLFSGSAYTVVSREYVGYVLQNEKIQKLMWAQDTYSPDEYLWATIQRIPEVPG  
 SLPASHKYDLSMDQAVARFVMDQYFEGDVSKGAPYPPCDGVHVRVSVICPGAGDLNWM  
 RQHHLFANKPDDVDLFAIQCLDEHLRHKALETLLH"  
 BASE COUNT 641 a 414 c 498 g 651 t  
 ORIGIN  
 1 gatttattgt gaaaactct ctctctctct ctctctctgt atatatatat atatatatat  
 61 atatatttat ttatatatat aattgcttct tttatttcag tgctgctctt catttcaaga  
 121 tgccgttgca gctctgataa atgcaactg acaaccttca aggccacgac ggagggaaga  
 181 tcattggtgc ttggagcata gaagactgcc cttcacaaag gaaatccctg attattgttt  
 241 gaaatgctga ggaagcttgc gcgaaggaga cttttttctt atcccaccaa atactacttt  
 301 atggttcttg tttatccct aatcaccttc tccgttttaa ggattcatca aaagcctgaa  
 361 tttgtaagtg tcagacactt ggagcttgct ggggagaatc ctagtagtga tattaattgc  
 421 accaaagtta tacagggtga tgtaaatgaa atccaaaagg taaagcttga gatcctaala  
 481 gtgaaattta aaaagcgccc tcggtggaca cctgacgact atataaacat gaccagtga  
 541 tggtcttctt tcataagag acgcaaatat attgtagaac cccttagtaa agaagaggcg  
 601 gagtttccaa tagcatattc tatagtgtt catcacaaga ttgaaatgct tgacaggctg  
 661 ctgagggcca tctatatgcc tcagaatttc tattgcgttc atgtggacac aaaatccgag  
 721 gattctatt tagctgcagt gatgggcatc gcttctgtt ttagtaattg ctttgtggcc

## FIGURE 9 (cont'd)

```

781 agccgattgg agagtgtggt ttatgcatcg tggagccggg ttcaggctga cctcaactgc
841 atgaaggatc tctatgcaat gagtgcacac tggaggtact tgataaatct ttgtggtatg
901 gattttccca ttaaaaccas cctagaaatt gtcaggaagc tcaagttgtt aatgggagaa
961 aacaacctgg aaacggagag gatgccatcc cataaagaag aaaggtggaa gaagcgggat
1021 gaggtcgta atggaagct gacaaacaca gggactgtca aaatgcttcc tccactcgaa
1081 acacctctct tttctggcag tgcctacttc gtggtcagta gggagtatgt ggggtatgta
1141 ctacagaatg aaaaaatcca aaagtgtgat gagtgggcac aagacacata cagccctgat
1201 gagtatctct gggccaccat ccaaaggatt cctgaagtcc cgggctcact ccctgccagc
1261 cataagtatg atctatctga catgcaagca gttgccaggt ttgtcaagtg gcagtacttt
1321 gaggggtgatg tttccaaggg tgctccctac ccgccctgcg atggagtcca tgtgcgctca
1381 gtgtgcattt tggagctgg tgacttgaac tggatgctgc gcaaacacca cttgtttgcc
1441 aataagtttg acgtggatgt tgacctctt gccatccagt gtttggatga gcatttgaga
1501 cacaagctt tggagacatt aaaacactga ccattacggg caattttatg aacaagaaga
1561 aggatacaca aaacgtaccc ttatctgttt ccccttcctt gtcagcatcg ggaagatggt
1621 atgaagtcct ctttggggca gggactctag tagatcttct tgtcagagaa gctgcattgt
1681 ttctgcagag cacagtttagc tagaaagggt atagcattaa atgttcatct agagttaata
1741 gtgggaggag taaaggtagc cttgaggcca gagcaggtag caaggcattg tggaaagagg
1801 ggaccagggt ggctggggaa gaggccgatg cataaagtc gctgttcaa agtgctcagg
1861 gacttagcaa aatgagaaga tgtgacctgt gccaaaacta ttttgagaat tttaaatgtg
1921 accatttttc tggatatgaat aaacttacag caacaaataa tcaaagatac aattaatctg
1981 atatttatatt tgttgaaata gaaatttgat tgtactataa atgatttttg taaataattt
2041 atattctgct ctaatactgt actgtgtagt gtgtctccgt atgtcatctc agggagctta
2101 aaatgggctt gatttaacat tgtttttgtg ttatttttgc ttgaaacaac gcacacattt
2161 tcaacaacca aaaaatgaca atttctagtt tagttaattt ctac

```

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**